[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.0.26. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
May 15, 1996

Carcinogenicity of Lipid-Lowering Drugs

JAMA. 1996;275(19):1481. doi:10.1001/jama.1996.03530430023030
Abstract

To the Editor.  —The article by Drs Newman and Hulley1 on carcinogenicity of lipid-lowering drugs has created a concern among patients and physicians that currently used lipid-lowering drugs may cause cancer. This concern almost certainly has led some patients to discontinue their drugs and others to avoid initiation of therapy. To date, however, there is no direct evidence in humans that lipid-lowering drugs cause cancer. Some meta-analyses of primary prevention trials have suggested that lipid-lowering drugs may increase noncardiovascular mortality. A lack of reduction in total mortality in these analyses raised the possibility that drug-induced noncardiovascular mortality might offset benefit in reduced cardiovascular morbidity and mortality. None of the meta-analyses, however, have specifically identified cancer deaths as a cause of increased noncardiovascular mortality.Recent clinical trials have largely dispelled concerns about an increase in noncardiovascular mortality as a consequence of cholesterol lowering. For example, meta-analysis of lipid-lowering trials in

×